Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18349588 | 0.85 | KDM4E (0.46) | MEN1TSHRKMT2ATAS1R3TAS1R1 | |
| SCHEMBL27444817 | 0.85 | MEN1 (0.44) | MEN1TSHRKMT2ATAS1R3TAS1R1 | |
| SCHEMBL21168954 | 0.84 | CDK5 (0.52) | MEN1TSHRKMT2ATAS1R3TAS1R1 | |
| SCHEMBL25964378 | 0.83 | MEN1 (0.55) | MEN1TSHRKMT2ATAS1R3TAS1R1 | |
| SCHEMBL26200096 | 0.80 | NPC1 (0.51) | MEN1TSHRKMT2ASMN1; SMN2KDM4E | |
| SCHEMBL14725444 | 0.78 | PI4KA (0.39) | MEN1TSHRKMT2A | |
| SCHEMBL24922819 | 0.76 | PI4KA (0.38) | MEN1TSHRKMT2A | |
| SCHEMBL10047156 | 0.76 | PI4KA (0.38) | MEN1TSHRKMT2A | |
| SCHEMBL26200392 | 0.75 | MEN1 (0.42) | MEN1TSHRKMT2ATAS1R3TAS1R1 | |
| SCHEMBL21654897 | 0.75 | RAF1 (0.43) | MEN1TSHRKMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271998-A1 | SOLID SUPPORT FOR SYNTHESIZING NUCLEIC ACID SEQUENCES AND METHODS FOR MAKING AND USING | RNGTT, NSUN2, POLN | MEN1 625/4885TSHR 3625/4885KMT2A 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.